Linkedin & Twitter

Wednesday, April 6, 2016

BREAKING NEWS: 
Pfizer calls off $160 billion Merger with Allergan 

  • Allergan CEO now says he's on the lookout for another deal
  • Pfizer plans to decide on potential split by end of year

Apr 6, 2016.- U.S. drugmaker Pfizer Inc (PFE.N) and Ireland-based Allergan Plc (AGN.N) walked away from their $160 billion merger on Wednesday, in an abrupt end to the largest-ever health-care deal after the U.S. government cracked down on corporate tax inversions.

The termination represents a victory for President Barack Obama, whose administration proposed tougher-than-expected new rules aimed at making inversions like the Pfizer-Allergan deal harder to achieve. In an inversion, a U.S. company shifts its tax address overseas, often through a merger.

The U.S. Treasury Department’s proposed new rules to deter companies from using acquisitions to shift their tax addresses overseas drove the decision, the companies said Wednesday in a statement. New York-based Pfizer will pay Allergan $150 million in reimbursement for expenses associated with the failed transaction.

Both companies are now left looking for their next move -- another deal, in Allergan’s case.

Allergan said it would move ahead with plans for its $40.5 billion sale of its generic drug business to Israel's Teva Pharmaceutical Industries (TEVA.TA). It expects the transaction to close by June.

“While this was not Plan A, we were prepared for this,” Allergan Chief Executive Officer Brent Saunders said in an interview on Bloomberg TV Wednesday. “We’re going to go and look to find assets that complement and increase our growth profile”.

Shares of Allergan, which fell 15 percent on Tuesday, were down 1.7 percent in premarket trading. Pfizer edged up 1.3 percent.

Pfizer, meanwhile, said it will decide whether to pursue a potential split of the company by no later than the end of this year. The split would probably involve two parts: one focused on new drug development, the other on selling older medications.

“The fact that the company is talking about the original split-up decision timeline of late 2016 almost seems to suggest they have given up on inversion,” Timothy Anderson, an analyst at Sanford C. Bernstein & Co., said of Pfizer’s decision.

Pfizer has new products coming and plenty of money that it could put to work with acquisitions, though not on the scale of Allergan, said Les Funtleyder, healthcare portfolio manager at E Squared Asset Management in New York, which holds Pfizer shares. It is not clear that Pfizer should definitely split into two, he said.

Valeant Unit?

Asked about whether he might be interested in buying Valeant Pharmaceuticals International Inc.’s eyecare unit, Bausch & Lomb, Saunders demurred, though did call it a premier asset. He declined to comment directly on what companies he might look at next.

Saunders said it wouldn’t have been in the best interests of his shareholders or Pfizer’s to fight the new rules.

“It would have been a long, protracted, expensive fight,” he said during the interview. “Perhaps we could have won, but that’s not a fair position to put our shareholders in, particularly when our stand-alone prospects, our growth prospects, our pipeline is so strong.”

Inversions Dead

With the Treasury rule, tax inversions -- dozens of which were performed by U.S. companies seeking to escape the country’s 35 percent corporate tax rate -- appear to be largely over.

“Inversions are dead,” said John Schroer, sector head of health care at Allianz Global Investors. Josh Earnest, a White House spokesman, said Tuesday that the administration hoped its new proposals would stop the transactions.

Allergan, which is run from New Jersey but has a legal domicile in Dublin, last year agreed to merge with Pfizer in a deal that would have given the New York-based company an Irish address and a lower tax rate.

Pfizer shares rose 1.2 percent to $31.75 at 9:44 in New York, while Allergan gained 1.3 percent to $239.65. Allergan will hold a call on Wednesday at 10 a.m. to discuss the breakup and the company’s next steps.

Pfizer still plans to report first-quarter earnings on May 3.

Sources: Bloomberg - Reuters - BioPharma DIVE
Haciendo click en cada uno de los links siguientes, Contenidos de nuestros 
TALLERES DE CAPACITACIÓN IN COMPANY, "A MEDIDA" 
de las necesidades de su Organización,
y aplicados específicamente al SECTOR SALUD Y FARMA:



Consultas al mail: medinacasabella@gmail.com
ó al TE: +5411.3532.0510


.·. Miguel Ángel MEDINA CASABELLA, MSM, MBA, SMHS .·.
Especialista en Management Estratégico, Gestión del Cambio e Inversiones
Representante de The George Washington University en Foros y Ferias de LatAm desde 2001
Representante de The George Washington University Medical Center para los Países de LatAm desde 1996
Ex Director Académico y Profesor de Gestión del Cambio del HSML Program para LatAm en GWU School of Medicine & Health Sciences (Washington DC)
CEO, MANAGEMENT SOLUTIONS GROUP LatAm
EMail: medinacasabella@gmail.com
TE Oficina: ( 0054) 11 - 3532 - 0510
TE Móvil (Local): ( 011 ) 15 - 4420 - 5103
TE Móvil (Int´l): ( 0054) 911 - 4420 - 5103
Skype: medinacasabella


MANAGEMENT SOLUTIONS GROUP LatAm ©
(medinacasabella@gmail.com; +5411-3532-0510)
es una Consultora Interdisciplinaria cuya Misión es proveer
soluciones integrales, eficientes y operativas en todas las áreas vinculadas a:

Estrategias Multiculturales y Transculturales, Organizacionales y Competitivas,
Management Estratégico,
Gestión del Cambio,
Marketing Estratégico,
Inversiones,
Gestión Educativa,
Capacitación

de Latino América (LatAm), para los Sectores:

a) Salud, Farma y Biotech,
b) Industria y Servicios,
c) Universidades y Centros de Capacitación,
d) Gobierno y ONGs.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)